Precision Technologies

Precision BioSciences is a clinical-stage biotechnology company dedicated to improving life through its proprietary genome editing platform, ARCUS. The company utilizes ARCUS, a unique nuclease-based editing technology derived from a natural genome editing enzyme, to perform highly specific in vivo gene editing and ex vivo cell therapies. While the company initially developed a robust pipeline of allogeneic CAR-T therapies, it has recently pivoted its primary focus toward in vivo gene editing applications for infectious diseases and genetic disorders. Their lead program, PBGENE-HBV, aims to provide a functional cure for chronic Hepatitis B by eliminating covalently closed circular DNA (cccDNA) and inactivating integrated HBV DNA.